Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says

Eli Lilly and Company (NYSE:LLY) had its target price upped by stock analysts at Rothschild & Co Redburn from $880.00 to $900.00 in a report released on Thursday,MarketScreener reports. Rothschild & Co Redburn’s price target would indicate a potential downside of 5.81% from the company’s previous close.

LLY has been the subject of a number of other reports. Bank of America dropped their target price on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating for the company in a report on Friday, May 1st. Berenberg Bank increased their price objective on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Leerink Partners dropped their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research report on Monday, April 27th. Zacks Research downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,218.33.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $19.47 during trading on Thursday, hitting $955.49. 747,904 shares of the company’s stock traded hands, compared to its average volume of 3,180,697. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm’s fifty day moving average price is $943.90 and its 200 day moving average price is $990.90. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a market cap of $899.82 billion, a PE ratio of 33.96, a PEG ratio of 1.08 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 35.68 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Oslo Pensjonsforsikring AS bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $2,733,000. HORAN Wealth LLC lifted its position in Eli Lilly and Company by 1.9% during the first quarter. HORAN Wealth LLC now owns 824 shares of the company’s stock worth $758,000 after acquiring an additional 15 shares during the last quarter. DJE Kapital AG bought a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $234,543,000. Andra AP fonden grew its position in shares of Eli Lilly and Company by 52.9% in the first quarter. Andra AP fonden now owns 127,233 shares of the company’s stock valued at $117,025,000 after purchasing an additional 44,003 shares during the last quarter. Finally, Wilkerson Advisory Group LLC lifted its holdings in Eli Lilly and Company by 18.9% during the 1st quarter. Wilkerson Advisory Group LLC now owns 1,454 shares of the company’s stock worth $1,337,000 after purchasing an additional 231 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat-and-raise drove momentum: Lilly’s strong Q1 (big revenue beat and raised guidance tied to Mounjaro/Zepbound/Foundayo strength) is cited as the primary catalyst for the rally. Analysts and commentators are framing the quarter as proof of durable demand. LLY Stock Pops 16% After Beat-and-Raise Q1
• Positive Sentiment: Major manufacturing and genetic‑medicine capacity build — Lilly committed an additional $4.5B to Indiana sites and opened its first LEAP genetic‑medicine facility, increasing API and genetic‑medicine output to support expected demand growth. This reduces future supply risk for high‑margin GLP‑1s and biologics. Lilly Announces Additional $4.5B Investment
• Positive Sentiment: Cantor Fitzgerald raised its price target after the Q1 call, signaling continued analyst confidence and supporting upside sentiment. Cantor Fitzgerald Lifts PT on Eli Lilly
• Positive Sentiment: Strategic M&A bolsters pipeline: Lilly’s ~$300M acquisition of CrossBridge Bio (Houston) adds biotech expertise and assets that complement its genetic‑medicine push. Meet the minds behind CrossBridge Bio
• Positive Sentiment: Clinical upside beyond weight loss: New positive data for Omvoh (mirikizumab) in ulcerative colitis (durable disease clearance in maintenance) supports pipeline diversification and longer‑term revenue optionality. Eli Lilly Advances As Inflammatory Bowel Disease Drug
• Neutral Sentiment: Governance stability: Shareholders backed the board and maintained the governance structure at the annual meeting — removes a near‑term proxy overhang. Shareholders Back Board
• Neutral Sentiment: Funding/financing chatter: Market chatter about Lilly planning bond sales to fund acquisitions circulated; the company responded — this could raise leverage but supports strategic investments if executed. Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds
• Negative Sentiment: Competitive pressure from Novo Nordisk: Novo’s strong pill launch and raised guidance highlight an intensifying global race in oral/peptide obesity drugs — investors worry about pricing pressure and market share erosion. Novo Could Win the Oral GLP‑1 Race
• Negative Sentiment: Critical analysis on earnings quality: Some pieces argue parts of the headline strength mask margin or sustainability questions — these narratives can cap near‑term multiple expansion. Earnings Are Weaker Than They Seem

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.